首页|1株西藏来源链霉菌10-37的次级代谢产物研究

1株西藏来源链霉菌10-37的次级代谢产物研究

扫码查看
目的 对1株西藏来源链霉菌10-37的次级代谢产物进行研究.方法 在分子网络指导下,利用HW40 C凝胶柱、Flash快速液相分离制备色谱仪、半制备型高效液相色谱等方法对化合物进行分离纯化,运用核磁共振、高分辨液质联用技术对单体化合物进行结构鉴定,最后利用微量肉汤稀释法进行抗菌活性测定.结果 从链霉菌10-37的菌丝体提取物中分离得到了4个代谢产物,包括2个新化合物oxazolomycin A3(1)和A4(2),以及2个已知化合物oxazolomycin A2(3)和oxazolomycin B(4).其中化合物1和2为化合物3的一对几何异构体,它们三烯部分的构型分别为(4'E,6'E,8'E)(1)、(4'Z,6'E,8'E)(2)、(4'Z,6'Z,8'E)(3)、(4'E,6'E,8'E)(4).结论 西藏特境的地理优势结合分子网络分析的策略,可以更高效地挖掘新结构次级代谢产物.
Secondary metabolites of Streptomyces sp.10-37 from Xizang
Objective This research studied the secondary metabolites of Streptomyces sp.10-37 collected in Xizang.Methods Under the guidance of the molecular network,the compounds were separated and purified by HW40 C gel columns,flash rapid liquid separation and preparation chromatographs,semi-preparative high-performance liquid chromatography and other methods.The structures of the purified compounds were identified by nuclear magnetic resonance and high-resolution liquid chromatography-mass spectrometry.Finally,the antibacterial activity was determined by the microbroth dilution method.Results Four metabolites were isolated and identified from the mycelium extract of Streptomyces sp.10-37,including two new compounds,oxazomycin A3(1)and A4(2),as well as two known compounds,oxazomycin A2(3)and oxazomycin B(4).Compounds 1 and 2 were a pair of geometric isomers of 3,with the configurations of their diene moieties being(4'E,6'E,8'E)(1),(4'Z,6'E,8'E)(2),(4'Z,6'Z,8'E)(3),and(4'E,6'E,8'E)(4),respectively.Conclusion The geographical advantages of Xizang's special environment,combined with the strategy of molecular network analysis,can better excavate new secondary metabolites.

StreptomycesSecondary metabolitesStructural identificationMolecular network

王嘉涵、常珊珊、陈铭旭、何宁、王梦源、解云英、袁丽杰

展开 >

华北理工大学基础医学院,河北省慢性疾病基础医学重点实验室,唐山市慢性病临床基础研究重点实验室,唐山 063210

中国医学科学院&北京协和医学院,医药生物技术研究所,药物合成生物学重点实验室,北京 100050

链霉菌 次级代谢产物 结构鉴定 分子网络

2024

中国抗生素杂志
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

中国抗生素杂志

CSTPCD北大核心
影响因子:1.08
ISSN:1001-8689
年,卷(期):2024.49(11)